BACKGROUND: Short-term outcomes using steroid-free immunosuppression after renal transplantation have been promising. No studies have examined the incidence of and reasons for steroid-avoidance protocol failures. METHODS: We present a single-center analysis of steroid-free immunosuppression failures among 129 pediatric renal transplant recipients with mean follow-up of 5 years. We analyzed causes for failure and examined reasons for conversion to steroid-based therapy. We compared actual patient and allograft survival and allograft function in the cohort of patients who required conversion to steroid-based immunosuppression with that of the cohort maintaining steroid-free immunosuppression. RESULTS: A total of 13.2% (17/129) of patients failed steroid-free immunosuppression. Actual patient survival was equivalent in the two cohorts, 96.4% for the cohort maintaining steroid-free immunosuppression and 94.1% for those requiring conversion. Actual allograft survival was lower in patients requiring conversion to a steroid-based protocol, 76.5% vs. 95.5% (P=0.004). Estimated glomerular filtration rates 12-months and 24-months posttransplant were greater in patients maintaining steroid-free immunosuppression (P=0.003). Most patients (52.9%, 9/17) who broke the steroid-free protocol did so because of refractory acute rejection. The second most common reason was recurrence of glomerulonephritis (GN; 35.3%, 6/17). CONCLUSION: The failure rate of steroid-free immunosuppression among selective pediatric patients undergoing renal transplantation is low. Patients maintaining steroid-free immunosuppression have better allograft survival and function than those requiring conversion to steroid-based therapy. The most common reasons for failure of steroid-free immunosuppression are recalcitrant or recurrent allograft rejection and recurrent GN; the role of conversion to steroid-based immunosuppression after episodes of acute rejection and recurrent GN requires additional analysis.
BACKGROUND: Short-term outcomes using steroid-free immunosuppression after renal transplantation have been promising. No studies have examined the incidence of and reasons for steroid-avoidance protocol failures. METHODS: We present a single-center analysis of steroid-free immunosuppression failures among 129 pediatric renal transplant recipients with mean follow-up of 5 years. We analyzed causes for failure and examined reasons for conversion to steroid-based therapy. We compared actual patient and allograft survival and allograft function in the cohort of patients who required conversion to steroid-based immunosuppression with that of the cohort maintaining steroid-free immunosuppression. RESULTS: A total of 13.2% (17/129) of patients failed steroid-free immunosuppression. Actual patient survival was equivalent in the two cohorts, 96.4% for the cohort maintaining steroid-free immunosuppression and 94.1% for those requiring conversion. Actual allograft survival was lower in patients requiring conversion to a steroid-based protocol, 76.5% vs. 95.5% (P=0.004). Estimated glomerular filtration rates 12-months and 24-months posttransplant were greater in patients maintaining steroid-free immunosuppression (P=0.003). Most patients (52.9%, 9/17) who broke the steroid-free protocol did so because of refractory acute rejection. The second most common reason was recurrence of glomerulonephritis (GN; 35.3%, 6/17). CONCLUSION: The failure rate of steroid-free immunosuppression among selective pediatric patients undergoing renal transplantation is low. Patients maintaining steroid-free immunosuppression have better allograft survival and function than those requiring conversion to steroid-based therapy. The most common reasons for failure of steroid-free immunosuppression are recalcitrant or recurrent allograft rejection and recurrent GN; the role of conversion to steroid-based immunosuppression after episodes of acute rejection and recurrent GN requires additional analysis.
Authors: Esther M Briganti; Graeme R Russ; John J McNeil; Robert C Atkins; Steven J Chadban Journal: N Engl J Med Date: 2002-07-11 Impact factor: 91.245
Authors: M M Sarwal; P D Yorgin; S Alexander; M T Millan; A Belson; N Belanger; L Granucci; C Major; C Costaglio; J Sanchez; P Orlandi; O Salvatierra Journal: Transplantation Date: 2001-07-15 Impact factor: 4.939
Authors: Cornelis G ter Meulen; Iza van Riemsdijk; Ronald J Hené; Maarten H L Christiaans; George F Borm; Teun van Gelder; Luuk B Hilbrands; Willem Weimar; Andries J Hoitsma Journal: Am J Transplant Date: 2004-05 Impact factor: 8.086
Authors: Khalid Khwaja; Massimo Asolati; James Harmon; J Keith Melancon; Ty Dunn; Kristen Gillingham; Raja Kandaswamy; Abhinav Humar; Rainer Gruessner; William Payne; John Najarian; David Dunn; David Sutherland; Arthur J Matas Journal: Am J Transplant Date: 2004-06 Impact factor: 8.086
Authors: Britta Höcker; Ulrike John; Christian Plank; Elke Wühl; Lutz T Weber; Joachim Misselwitz; Wolfgang Rascher; Otto Mehls; Burkhard Tönshoff Journal: Transplantation Date: 2004-07-27 Impact factor: 4.939
Authors: Minnie M Sarwal; Jayakumar R Vidhun; Steven R Alexander; Thomas Satterwhite; Maria Millan; Oscar Salvatierra Journal: Transplantation Date: 2003-11-15 Impact factor: 4.939
Authors: Aleksandra Kukla; Eric Chen; Richard Spong; Marc Weber; Yasser El-Shahawi; Kristen Gillingham; Arthur J Matas; Hassan N Ibrahim Journal: Transplantation Date: 2011-06-27 Impact factor: 4.939
Authors: Abanti Chaudhuri; Mikki Ozawa; Matthew J Everly; Robert Ettenger; Vikas Dharnidharka; Mark Benfield; Robert Mathias; Anthony Portale; Ruth McDonald; William Harmon; David Kershaw; V Matti Vehaskari; Elaine Kamil; H Jorge Baluarte; Bradley Warady; Li Li; Tara K Sigdel; Szu-chuan Hsieh; Hong Dai; Maarten Naesens; Janie Waskerwitz; Oscar Salvatierra; Paul I Terasaki; Minnie M Sarwal Journal: J Am Soc Nephrol Date: 2013-02-28 Impact factor: 10.121